Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a pioneering clinical-stage biopharmaceutical company located in Boston, Massachusetts. The company focuses on developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells directly within the patient's body. Cue Biopharma’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), aims to harness the body’s intrinsic immune system as T cell engagers, minimizing the need for ex vivo manipulation and broad systemic immune modulation.
The company's leading clinical programs include CUE-101 and CUE-102. CUE-101 is being evaluated for the treatment of recurrent/metastatic HPV16+ head and neck squamous cell carcinoma both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). Recent data from Phase 1 trials have shown promising results, including prolonged overall survival and enhanced clinical activity when combined with pembrolizumab.
CUE-102 targets Wilms' Tumor 1 (WT1)-expressing cancers such as colorectal, gastric, and pancreatic cancers. Early Phase 1 trial data for CUE-102 has demonstrated expansion of WT1-specific T cells and favorable tolerability, pointing to potential therapeutic benefits for cancers resistant to traditional treatments.
Additionally, Cue Biopharma is advancing its preclinical program CUE-401 for autoimmune and inflammatory diseases in collaboration with Ono Pharmaceutical. This program aims to redirect virus-specific T cells to deplete B cells in autoimmune conditions.
Financially, Cue Biopharma reported increased collaboration revenue due to its strategic agreement with Ono Pharmaceutical. Despite higher research and development expenses, the company maintains a strong cash position, with approximately $41 million in cash and equivalents expected to fund operations into the first quarter of 2025. The management team, led by CEO Daniel Passeri, continues to focus on strategic corporate objectives, including potential registrational trials for CUE-101 and advancing other therapeutic candidates.
With an experienced leadership and independent Board of Directors, Cue Biopharma is well-positioned to make significant strides in the fields of oncology and autoimmune disease treatment, aiming to deliver transformative therapies for patients while creating value for its shareholders.
On April 25, 2023, Cue Biopharma (Nasdaq: CUE) announced the appointment of Dr. Pamela D. Garzone to its board of directors. Dr. Garzone brings over 25 years of experience in the healthcare and pharmaceutical sectors, particularly in drug development and regulatory leadership. Her expertise spans various therapeutic areas, including immuno-oncology, which aligns with Cue Biopharma’s focus on developing innovative biologics aimed at engaging disease-specific T cells within patients. Cue Biopharma aims to enhance treatment options for cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. The CEO, Daniel Passeri, expressed confidence that Dr. Garzone’s experience will provide strategic insights as the company advances its clinical and preclinical pipeline.
Cue Biopharma (CUE) has announced the appointment of Patrick Verheyen to its Board of Directors, bringing over 35 years of experience from Janssen Pharmaceutical. Verheyen's expertise in business development and M&A is expected to enhance Cue's corporate growth and current drug candidates, CUE-101 and CUE-102. Daniel Passeri, CEO of Cue Biopharma, expressed enthusiasm for Verheyen's insights, aiming to broaden the company’s strategic initiatives in immunotherapy for autoimmune diseases and cancer. Verheyen's past achievements include leading significant acquisitions at Janssen, which expanded its pipeline and established a global innovation presence.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
What is Cue Biopharma's main focus?
What are CUE-101 and CUE-102?
Where is Cue Biopharma headquartered?
What is the Immuno-STAT™ platform?
Who are Cue Biopharma’s strategic partners?
What recent financial achievements has Cue Biopharma made?
What is the status of the CUE-101 clinical trials?
What does the CUE-102 program aim to achieve?
What is CUE-401?
What is the company's financial outlook?
